GlobeNewswire by notified

Implementation of share buy-back programme

Share

Nasdaq Copenhagen
London Stock Exchange        
Euronext Dublin
Other stakeholders

Date    1 February 2023


Implementation of share buy-back programme

The bank’s board of directors decided today to implement a share buy-back programme totalling DKK 385 million with a view to cancelling the shares at a future general meeting.

The share buyback programme is based on the general authority which the bank’s annual general meeting held the 2 March 2022 gave the bank’s board of directors to permit the bank to acquire own shares.

The share buy-back programme runs from 2 February 2023 up to and including 27 July 2023 provided that the forthcoming annual general meeting, to be held on 1 March 2023, gives the board a new authority to permit the bank to acquire its own shares.

During this period the bank will buy its own shares for up to DKK 385 million under the programme, subject to a maximum of 1,000,000 shares.

The share buy-back programme will be implemented in compliance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) No 2016/1052 of 8 March 2016, which together constitute the Safe Harbour regulation.

The bank may suspend or stop the buy-back of shares at any time, in which event a corporate announcement will be issued.

The conditions for the share buy-back programme are as follows:

  • The purpose of the share buy-back is to adjust the bank’s capital structure.
  • Ringkjøbing Landbobank has appointed Danske Bank as lead manager of the share buy-back programme. Danske Bank will make all trading decisions independently, without influence from Ringkjøbing Landbobank, and will purchase shares within the published limits.
  • The maximum amount that Ringkjøbing Landbobank may pay for shares purchased under the programme is DKK 385 million, while a maximum limit of 1,000,000 shares may be acquired.
  • Shares may not be purchased at a price exceeding the higher of (i) the price of the latest independent transaction; and (ii) the highest bid from an independent buyer on Nasdaq Copenhagen at the time of the transaction.
  • The total number of shares that may be purchased on a single trading day may not exceed 25% of the average daily traded volume over the preceding 20 trading days on Nasdaq Copenhagen.
  • Ringkjøbing Landbobank will announce the number of purchased shares, as well as their value, on a weekly basis in a separate announcement to Nasdaq Copenhagen, in both aggregated and detailed forms.

Yours faithfully

Ringkjøbing Landbobank


John Fisker
CEO

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,

Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse

Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør

Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse

Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er fore­taget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag

Forløb af ordinær generalforsamling i Investeringsforeningen ValueInvest Danmark den 19. april 202419.4.2024 11:30:00 CEST | pressemeddelelse

Bestyrelsens beretning Bestyrelsens beretning blev taget til efterretning. Årsrapport, udbytte og bestyrelsesmedlemmernes honorar Årsrapporten for 2023 blev enstemmigt godkendt, herunder bestyrelsens honorar samt forslag om udbetaling af udbytte på 13,60 kr. pr. bevis for andelsklasse A i ValueInvest Global KL, og udbytte på 14,60 kr. pr. bevis for andelsklasse W i ValueInvest Global KL. Udbyttebetalingen til investorerne er foretaget aconto den 5. februar 2024. Forslag fremsat af bestyrelsen Der blev ikke fremsat forslag under dette punkt. Valg til bestyrelsen Bestyrelsen havde indstillet til genvalg af Ole Steffensen, Jens Harck og Bent Erik Carlsen, der enstemmigt blev valgt som medlemmer af bestyrelsen. Valg af revisor EY Godkendt Revisionspartnerselskab blev genvalgt som revisor. Med venlig hilsen Bestyrelsen for Investeringsforeningen ValueInvest Danmark c/o BI Management A/S Bredgade 40 1260 København K

HiddenA line styled icon from Orion Icon Library.Eye